Teva finds regulatory VP at FDA gate

Generics-maker Teva Pharmaceutical has hired Gary Buehler, FDA's former head of generic drugs and outgoing deputy director, Office of Pharmaceutical Science. Buehler is set to retire from the FDA at the end of this week. He'll join Teva as VP for regulatory strategic operations. The drugmaker no doubt hopes to tap Buehler's insider insights for generics and biosimilars. Article

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.